Результаты поиска

Old Drugs, New Battles: Unleashing Repurposed Drug Classes in Triple-Negative Breast Cancer Treatment.

Cancer remains a major global health challenge, with triple-negative breast cancer (TNBC) representing one of the most aggressive and difficult-to-treat subtypes, characterized by poor prognosis and limited therapeutic options. Current treatments, including chemotherapy, are hindered by high recurrence rates, drug resistance, and severe side effects, highlighting the urgent need for novel therapeutic strategies to address these challenges. Drug repurposing, which involves the application of existing FDA-approved (Food and administration) drugs for new oncological uses, offers a cost-effective

Совпадение в полном тексте источника
… Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine and paroxetine, have been shown to induce apoptosis in TNBC cells by targeting the PI3K/AKT/mTOR signaling pathway, which is critical for cell survival and proliferation [ 55 ]. … By modulating autophagy and apoptosis pathways, antidepressants such as fluoxetine and imipramine enhance the efficacy of chemotherapy and targeted treatment [ 60 ]. …

Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics.

Since November 2019 the SARS-CoV-2 pandemic has caused nearly 200 million infection and more than 4 million deaths globally (Updated information from the World Health Organization, as on 2nd Aug 2021). Within only one year into the pandemic, several vaccines were designed and reached approval for the immunization of the world population. The remarkable protective effects of the manufactured vaccines are demonstrated in countries with high vaccination rates, such as Israel and UK. However, limited production capacities, poor distribution infrastructures and political hesitations still hamper th

Совпадение в полном тексте источника
… Fluoxetine Recently, the therapeutic effect of Functional Inhibitors of Acid Sphingomyelinase (FIASMA) such as the antidepressant Fluoxetine to inhibit SARS-CoV-2 cell entry has been investigated by several groups. … This revealed, that Fluoxetine treatment efficiently reduced viral entry and replication without cytotoxic effects in vitro ( 96 , 97 ). …

Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.

OBJECTIVES: To investigate the clinical effectiveness and cost-effectiveness of naltrexone for relapse prevention in detoxified formerly opi … RRs of stopping treatment were 1.63 at 6 months and 1.31 at 12 months (in favour of naltrexone plus fluoxetine). It became statistically significant at 6 months, but not at 12 months. A meta-analysis of the RR of stopping treatment at week 12 (the minimum follow-up period) was carried out using six of the nine studies. The pooled RR of stopping treatment was …

Irritable Bowel Syndrome.

I believe there are four essential elements in the management of patients with irritable bowel syndrome (IBS): to establish a good physician … with mild to moderate co-morbid depression, I have found that the use of SSRIs such as paroxetine, fluoxetine, or sertraline may be beneficial. It is important to tell patients that anxiety and disturbed sleep may occur during the first 10 days and benefits may not occur for 3 to 4 weeks. I prescribe a small amount of a short-acting benzodiazepine such as a …

Навязчивое сексуальное поведение у депрессивных женщин

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… She was started on oral treatment with selective serotonergic reuptake inhibitor (SSRI) fluoxetine 20 mg and its dosage was increased to 60 mg in 2 months' period along with the behavior therapy. …

Implications of Systemic Inflammation and Periodontitis for Major Depression.

Increasing evidence suggests that infection and persistent low-grade inflammation in peripheral tissues are important pathogenic factors in major depression. Major depression is frequently comorbid with systemic inflammatory diseases/conditions such as rheumatoid arthritis, allergies of different types, multiple sclerosis, cardiovascular disease, inflammatory bowel disease, chronic liver disease, diabetes, and cancer, in which pro-inflammatory cytokines are overexpressed. A number of animal studies demonstrate that systemic inflammation induced by peripheral administration of lipopolysaccharid

Совпадение в полном тексте источника
… A cross-sectional clinical study also showed that intake of fluoxetine, another type of antidepressants (i.e., selective serotonin reuptake inhibitor), is associated with lower bleeding on probing percentages and lower attachment loss in patients with chronic periodontitis and clinical depression ( Bhatia … Effect of fluoxetine on periodontal status in patients with depression: a cross-sectional observational study. J. Periodontol. 86 927 – 935 . 10.1902/jop.2015.140706 25812910 Biesmans S. Meert T. F. Bouwknecht J. A. Acton P. D. Davoodi N. De Haes P. ( 2013 ). …

Repurposed Drugs in Gastric Cancer.

Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC treatment approaches involve endoscopic detection, gastrectomy and chemotherapy or chemoradiotherapy in an adjuvant or neoadjuvant setting. Drug development approaches demand extreme effort to identify molecular mechanisms of action of new drug candidates. Drug repurposing is based on the research of

Совпадение в полном тексте источника
… In AGS GC cells, fluoxetine inhibits cell proliferation. Additionally, apoptosis induced by fluoxetine is associated with an increase in activated caspases and PARP cleavage. … Therefore, fluoxetine may be a promising therapeutic agent for GC treatment [ 48 ]. …

Targetable pathways for drug repurposing in gastric cancer.

Gastric cancer (GC) is both the fifth most common cancer worldwide and the fifth in mortality. Owing to a lack of symptoms in the early stages and unspecific clinical presentation in the later stages, GC is usually diagnosed at advanced stages. This means that only approximately 60% of patients are eligible for curative treatment, and overall, GC patients have a 5-year survival rate of only 28.3%, underscoring the importance of developing new treatment strategies. Drug repurposing involves identifying new therapeutic uses for approved drugs and is a promising strategy for cancer treatment beca

Совпадение в полном тексте источника
… The antidepressant fluoxetine is typically used to treat cancer-related depression. Fluoxetine has also been shown to have anticancer activity[ 105 ] and may be a promising candidate for drug repurposing[ 29 ]. … According to a recent study, fluoxetine induces apoptosis through the death receptor pathway. However, fluoxetine also increases autophagocytosis, which can reduce apoptosis. The combination of fluoxetine and an autophagy inhibitor, 3-methyladenine, increased the apoptotic effect of fluoxetine. …

Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.

BACKGROUND: Selective serotonin reuptake inhibitors (SSRIs) might theoretically reduce post-stroke disability by direct effects on the brain … ss all domains; all six studies did not need participants to have depression to enter, and all used fluoxetine. Of these six studies, there was little to no difference in disability between groups SMD -0.0; 95% CI -0.05 to 0.05; 5 studies, 5436 participants, high-quality evidence) or in independence (RR 0.98; 95% CI 0.93 to 1.03; 5 studies, 5926 participants …

Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder.

BACKGROUND: Premenstrual syndrome (PMS) is a combination of physical, psychological and social symptoms in women of reproductive age, and pr … ngs using GRADE. MAIN RESULTS: We included 34 RCTs in the review. The studies compared SSRIs (i.e. fluoxetine, paroxetine, sertraline, escitalopram and citalopram) to placebo. SSRIs probably reduce overall self-rated premenstrual symptoms in women with PMS and PMDD (SMD -0.57, 95% CI -0.72 to -0.42; I2 = 51%; 12 studies, 1742 participants; moderate-certaint …

[Psychiatric and psychological aspects of premenstrual syndrome].

Numerous, but heterogeneous studies have been performed about premenstrual syndrome, with finally a lack of credibility and interest among p … menstrual dysphoric disorder were performed in the beginning of the nineties, with clomipramine and fluoxetine, and later fluvoxamine, paroxetine, sertraline and citalopram. Studies having compared the efficiency of antidepressants according to their serotonin activity (paroxetine or sertraline versus maprotiline, that is a selective noradrenaline re-uptake …

Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies.

Progressive forms of multiple sclerosis (MS) include primary progressive MS (PPMS) and secondary progressive MS (SPMS). Unlike relapsing-remitting MS (RRMS), progressive MS is recognized by relentless progression with accumulating disability, rare to no relapses nor new activity on MRIs. Clinically, neurologic worsening in MS can occur in the relapsing-remitting (RRMS) phase of disease due to incomplete recovery from neuroinflammatory relapses. However, a progressive disease course is the dominant factor related to accumulating disability. There is persistent central nervous system (CNS) compa

Совпадение в полном тексте источника
… Depression SSRIs (e.g. sertraline, fluoxetine, citalopram, etc), SNRIs, (e.g. duloxetine, venlafaxine) bupropion, mirtazapine, trazodone Antidepressants are commonly used in MS patients. Gait abnormality Dalfampridine Used to improve walking. … Depression SSRIs (e.g. sertraline, fluoxetine, citalopram, etc), SNRIs, (e.g. duloxetine, venlafaxine) bupropion, mirtazapine, trazodone Antidepressants are commonly used in MS patients. Gait abnormality Dalfampridine Used to improve walking. Drugs used for symptom management in progressive MS. …

Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?

Multiple system atrophy is a rapidly progressive and fatal neurodegenerative disorder. While numerous preclinical studies suggested efficacy of potentially disease modifying agents, none of those were proven to be effective in large-scale clinical trials. Three major strategies are currently pursued in preclinical and clinical studies attempting to slow down disease progression. These target α-synuclein, neuroinflammation, and restoration of neurotrophic support. This review provides a comprehensive overview on ongoing preclinical and clinical developments of disease modifying therapies. Furth

Совпадение в полном тексте источника
… In a transgenic MSA mouse model fluoxetine has been shown to increase GDNF and BDNF levels and to suppress pro-inflammatory cytokines [ 161, 162 ]. … A phase II randomized placebo-controlled trial of fluoxetine in MSA patients failed to demonstrate fluoxetine superiority over placebo on the total UMSARS score, whereas trends in motor and emotional secondary/exploratory outcomes deserve further investigation [ 163 ]. …

Повторение повторяющихся поведенческих паттернов: серия случаев с компульсивным поведением, трicho-тillomania, ненужной саморазрушительной поведенческой активностью и синдромом жаждущего еды.

Заболевание вынужденного сексуального поведения (CSBD), трichoэпилепсия (TTM), расстройство жор (BED) и ненужное самоповреждение (NSSI) классифицируются в отдельных категориях в Межправительственной классификации болезней, 11-е издание (ICD-11). В этом серийном случае旨在 explore общие импульсивные и вынужденные черты этих расстройств, несмотря на их общую феноменологию и сопутствующие расстройства. Также обсуждается инсайт, механизмы вознаграждения и связанные нейробиологические понимания повторяющихся действий. В конце также подчеркивается потенциальная роль глиаминергических препаратов в их л

Совпадение в полном тексте источника
… He was started on Fluoxetine 20 mg per day and increased to 60 mg daily for contamination-related OCD. Naltrexone 50 mg daily was added to manage more disabling sexual urges, considering it to be impulsive. … The patient responded well to a treatment regimen, including NAC 600 mg twice a day, lamotrigine 150 mg per day, and Fluoxetine 40 mg per day. An additional diagnosis of NSSI was considered. Her behaviors were assessed on Y-BOCS with a score reduction from 28 to 12 in three months. …

NLRP3 воспаление в нейро-воспалении и заболеваниях центральной нервной системы.

Нейроинфламмация играет важную роль в патогенезе различных заболеваний центральной нервной системы (КНС). NLRP3 является важным внутриклеточным многопротеиновым комплексом, состоящим из врожденного иммунного рецептора NLRP3, адаптационного белка ASC и протеза каспе-1. Активация NLRP3 испарения может вызвать пироптоз и высвобождение проинфламамина IL-1β и IL-18, тем самым играя центральную роль в иммунной и подстрекательской реакции. Недавние исследования показали, что воспаление NLRP3 активируется в мозгу, с тем чтобы вызвать нейроинфламму, что приводит к дальнейшим нейронным повреждениям и фу

Совпадение в полном тексте источника
… Many compounds, such as fluoxetine, MCC950 and berberine, block depression by inhibiting the NLRP3 inflammasome [ 139 ]. Fluoxetine exerts its therapeutic effects by targeting the antioxidant Nrf2/HO-1 and inhibiting the TLR4/NLRP3 inflammasome signaling pathway [ 140 ]. …

Emerging therapeutic strategies in glioblastsoma: drug repurposing, mechanisms of resistance, precision medicine, and technological innovations.

Glioblastoma (GBM) is an aggressive Grade IV brain tumor with a poor prognosis. It results from genetic mutations, epigenetic changes, and factors within the tumor microenvironment (TME). Traditional treatments like surgery, radiotherapy, and chemotherapy provide limited survival benefits due to the tumor's heterogeneity and resistance mechanisms. This review examines novel approaches for treating GBM, focusing on repurposing existing medications such as antipsychotics, antidepressants, and statins for their potential anti-GBM effects. Advances in molecular profiling, including next-generation

Совпадение в полном тексте источника
… Fluoxetine Fluoxetine induces glioma cell death without harming healthy cells. It promotes mitochondrial damage by increasing calcium influx via GluR1, leading to apoptosis through caspase activation [ 102 ]. … Emerging therapeutic strategies such as targeted therapies, immunotherapy, tumor-treating fields, and drug repurposing (e.g., fluoxetine, metformin, and disulfiram) offer new hope in improving treatment efficacy. …

Novel Strategies for Cancer Combat: Drug Combination Using Repurposed Drugs Induces Synergistic Growth Inhibition of MCF-7 Breast and HT-29 Colon Cancer Cells.

Our group developed a new model of drug combination consisting of the use of antineoplastic drugs and different repurposed drugs, having demonstrated that antimalarial and central nervous system (CNS) drugs have a promising anticancer profile as standalone agents, as well as in combined regimens. Here, we evaluated the anticancer profiles of two different CNS drugs (edaravone and quetiapine), both alone and in combination with antineoplastic agents for breast and colon cancer, to explore whether these repurposed drugs could synergistically enhance the anticancer potential of chemotherapeutic d

Совпадение в полном тексте источника
… Collectively, we studied the combined use of two antimalarial (pyronaridine and mefloquine) and two CNS drugs (fluoxetine and sertraline) on the MCF-7 and HT-29 cancer cell lines. … | Drug | HT-29 | MCF-7 IC 50 (µM) | IC 50 (µM) CNS | Fluphenazine | 1.86 | 2.68 Fluoxetine | 6.12 | 7.78 Benztropine | 18.23 | 21.71 Thioridazine | 4.26 | 5.72 Sertraline | 2.45 | 2.22 Entacapone | 40.89 | ND Tolcapone | 35.47 | ND Edaravone | >50 | >50 Quetiapine | 15.19 | >50 Antimalarials | Artesunate …

Rare complication of a commonly used antihypertensive agent: A case of hydralazine-induced ANCA-associated vasculitis presenting as rapidly progressive glomerulonephritis.

Hydralazine-induced ANCA-associated vasculitis is a rare clinical entity, with complications including rapidly progressive glomerulonephritis, pulmonary hemorrhage, and pulmonary-renal syndrome. We present this case to highlight the clinical features that support this challenging diagnosis and to emphasize the importance of prompt recognition and aggressive intervention given its significant morbidity and mortality.

Совпадение в полном тексте источника
… Her home medications included hydralazine 50 mg three times daily (treatment for upwards of three years) as well as apixaban, clopidogrel, isosorbide mononitrate, metoprolol succinate, simvastatin, valsartan, furosemide, famotidine, febuxostat, and fluoxetine. …

Voltage-gated sodium channel as a target for metastatic risk reduction with re-purposed drugs.

ObjectiveTo determine the exact role of sodium channel proteins in migration, invasion and metastasis and understand the possible anti-invasion and anti-metastatic activity of repurposed drugs with voltage gated sodium channel blocking properties.Material and methodsA review of the published medical literature was performed searching for pharmaceuticals used in daily practice, with inhibitory activity on voltage gated sodium channels. For every drug found, the literature was reviewed in order to define if it may act against cancer cells as an anti-invasion and anti-metastatic agent and if it w

Совпадение в полном тексте источника
… Other drugs Other drugs that have shown significant VGSC blocking activity and may have activity in the fight against migration, invasion and metastasis are: fluoxetin blocks NaV1.5 124 , and mexiletine 125 . … Anesthesiology. 2012 ; 117 ( 3 ): 548 – 559 . 10.1097/ALN.0b013e3182661977 22846676 PMC3482823 124 Poulin H Bruhova I Timour Q : Fluoxetine blocks Na v 1.5 channels via a mechanism similar to that of class 1 antiarrhythmics. …

Psychological and pharmacological interventions for depression in patients with coronary artery disease.

BackgroundDepression occurs frequently in individuals with coronary artery disease (CAD) and is associated with a poor prognosis.ObjectivesT … ptoms at end of treatment is very uncertain for: simvastatin versus atorvastatin; paroxetine versus fluoxetine; and escitalopram versus Bu Xin Qi. No trials were eligible for the comparison of a psychological intervention with a pharmacological intervention.Authors' conclusionsIn individuals with CAD and depression, there is low certainty evidence that psych …